Radboud University Medical Centre Nijmegen (RAD)

website

Radboud University Medical Centre Nijmegen aims to have a significant impact on healthcare by providing excellent quality of care and research with a focus on participatory and personalized healthcare. The participating departments of the Radboudumc are: ‘Diagnosis and Imaging Analysis Group (diagnijmegen.nl)’, ‘Radiology, Nuclear Medicine and Anatomy’, and ‘Pathology’. DIAG is a world-leading group on deep learning in medical imaging, with 50PhD students and 11 staff members. DIAG spin-offs include Screenpoint Medical and Thirona that develop and sell AI products for breast cancer screening, quantifying lung disease.

Role in PANCAIM:

  • Project leader/management
  • Research radiology/pathology AI biomarkers and
  • Research radiology/pathology multimodal AI applications
  • Clinical validation of AI applications
key staff

Henkjan Huisman – Project Coordinator

Show Bio
Henkjan Huisman, PhD is associate professor of radiology on AI for medical imaging at the Radboud University Medical Center, The Netherlands. He has over 30 years of experience in scientific research, prototyping, and clinical validation of medical imaging AI. His research team explores and uses AI to better understand disease, diagnosis, and therapy in the field of abdominal radiology aiming to improve healthcare. He is co-founder of QView Medical and DIAGTechnologies for developing AI for breast ultrasound and prostate MRI respectively. He has an overall h-index of 41 is part of the Computer Aided Image Analysis AAPM committee (TG273) and serves as associate editor for several journals. He is (co-)organizer of several high-profile challenges in medical imaging such as PROMISE12 and ProstateX.

John Hermans

Show Bio
John Hermans, MSc, MD, PhD is both an engineer in Chemical Technology as well as a Medical Doctor in Radiology and Nuclear Medicine. He was appointed as radiology consultant first at the Erasmus University in Rotterdam and since then at the Radboud University Medical Center in Nijmegen. He dedicated his research to imaging of pancreas pathology, such as pancreatitis, trauma and especially pancreatic cancer. Currently he is workgroup leader in ‘Advanced Imaging Techniques in Pancreas Pathology’ and applies AI to analyse CT and MR images to optimize personalized treatment. Currently he is PI of an international study implementing MRI for early detection of liver metastases in pancreatic cancer (DIA-PANC) and a national study on CT perfusion to define a vascular phenotype of pancreatic cancer (PERFUSION-PANC).

Geert Litjens

Show Bio
Geert Litjens, PhD is an assistant professor of Computational Pathology at the Radboud University Medical Center. His research is at the intersection of machine learning, medical imaging, and oncology. He co-chairs the Computational Pathology Group, which develops automated machine learning systems for cancer detection, biomarker discovery and quantification, and improved prognostication. He is also the developer of the ASAP software package for analyzing and visualizing whole-slide images and (co-)organizer of several high-profile challenges in medical imaging such as PROMISE12 and CAMELYON. He (co-)authored over 60 publications in medical, imaging, and machine learning conferences and journals.

Pierpaolo Vendittelli

Show Bio
Pierpaolo Vendittelli, MSc. is a PhD Candidate of the Computational Pathology Group and the Diagnostic Image Analysis Group at the Radboud University Medical Center. His role in PANCAIM will be research of new biomarkers in pathology.

Natália Alves

Show Bio
Natália Alves, MSc. is a PhD Candidate at the Diagnostic Image Analysis Group at the Radboud University Medical Center working on the application of deep learning to radiology in order to develop new biomarkers for pancreatic cancer.

Megan Schuurmans

Show Bio
Megan Schuurmans, MSc. is a PhD Candidate at the Diagnostic Image Analysis Group at the Radboud University Medical Center working on the application of AI to analyse CT and MR images to optimize personalized treatment and implementation of MRI for early detection of liver metastases in pancreatic cancer (DIA-PANC).

Karolinska Institutet (KI)

website

The Karolinska Institute is Sweden’s single largest centre of medical academic research and offers the country’s widest range of medical courses and programmes. It is closely affiliated with Karolinska University Hospital, the largest and most highly specialized medical centre of the Stockholm Region. The unit for upper gastrointestinal diseases at its Cancer Division is the nationally leading center for pancreatic diseases and comprises the full spectrum of pancreatic surgeons, gastroenterologists and clinical oncologists who treat approximately 100 patients with pancreatic cancer at any given time point and performs approximately 250 pancreatic operations per year. Participating researchers from Karolinska Institutet represent a larger multi-center collaboration, the CaMChaTCa project, that was established as a project group in the Pancreas 2000 educational program (https://www.pancreas2000.org/). Pancreas 2000 is a non-profit organization registered in Austria. The CaMChaTCa project curates a well-defined retrospective cohort of pancreatic cancer patients across four centers in Sweden and Germany (Karolinska University Hospital, Stockholm; Norrlands Universitety Hospital, Umeå; University Hospital of Munich (LMU), and University Medicine Göttingen).

Role in PANCAIM:

Karolinska Institutet, on behalf of CaMChaTCa / Pancreas 2000, contributes clinical expertise in the surgical and oncological treatment of pancreatic cancer throughout the project. KI team will contribute multilayer data (Genomics, clinical data, medical images and other omics) to the PANCAIM repository. They will evaluate and test how accurately the algorithms can predict relevant clinical outcomes. They will also amend and harmonize the molecular information available in their dataset and integration of this information into the repository to allow for a sufficient number of data-rich cases. KI team provides expertise in health management, ethics and economics via the Karolinska Institutet’s Department of Learning, Informatics, Management and Ethics (LIME) and will conduct the Health Technology Assessment. They will take a major role in development of clinical guidelines on the implementation of clinical AI tool.

key staff

Matthias Löhr

Show Bio
Matthias Löhr is a Professor of Gastroenterology & Hepatology at Karolinska Institutet. He is leading the KICancer Network on Pancreatic Tumors and in the steering committee of the KI Personalised Cancer medicine program. He is the secretary of the European Pancreas Club (EPC). Prof. Löhr’s research focusses on pancreatic diseases, both clinically and in the lab. He conducted several early phase clinical studies as a PI in pancreatic cancer (CT-PCA-1, EndoTAG-1, AXP107- 11), including a first personalized cancer medicine study in pancreatic cancer, PePaCaKa-01. Prof. Löhr earned his MD at the Medical School of the University of Hamburg in Germany where he also did his MD thesis work. He is also holding an American MD (ECFMG). After graduating in 1986, he was a resident in pathology at the University of Hamburg before he took a postdoctoral fellowship at the Department of Immunology, Scripps Clinic & Research Foundation, La Jolla, CA. Returning in 1989 to Germany, he started in Internal Medicine at the Univ. of Erlangen. In 1993, he became chief resident and later attending physician at the Univ. of Rostock. Here, he also finished his PhD (Dr. med. habil./Privatdocent). In 2000, he was appointed Professor of Molecular Gastroenterology at the Univ. of Heidelberg and became Head of the identical named division at the German Cancer Research Center (DKFZ). In 2007, he was appointed as the professor of Gastroenterology & Hepatology at Karolinska Institutet. Löhr is leading the European Educational Program for Future Pancreatologists, “Pancreas 2000”. He was part of several EU-funded projects, MolDiaPaCa, EPC-TM-Net, CanDo, PRECODE (ongoing).

Maximilian Kordes

Show Bio
Maximilian Kordes is a specialist physician (Clinical oncology) at Karolinska University Hospital, Huddinge and PhD student in Prof. Löhr’s research group. Maximilan established, together with Stina Lindblad, the infrastructure for the CaMChaTCa project. His research projects focus on the prediction of clinical outcomes using readily available data and the detection of tumor-specific molecular signatures in liquid biopsies of pancreatic cancer patients. Maximilian graduated from the University of Heidelberg Medical School in Germany and did his MD Thesis work at the Max- Planck-Institute for Infection Biology in Berlin on innate immune responses against the Malaria parasite. He did his residency at the National Center for Tumor Diseases in Heidelberg (Internal Medicine Oncology/Hematology) and later at Karolinska University Hospital in Stockholm (Clinical Oncology). He obtained his certification as a specialist in Clinical Oncology in 2019.

Mats Brommels

Show Bio
Mats Brommels, MD, PhD is professor emeritus of medical management, former Chair of the Department of Learning, Informatics, Management and Ethics (LIME) and Director, Medical Management Centre (MMC), Karolinska Institutet. Joined Karolinska Institutet in 2002 to establish the MMC. Previously he was a professor of health management at the Nordic School of Public Health, Gothenburg, Sweden, and the University of Helsinki, Finland. He is a specialist in internal medicine and a disease classification expert. His research covers the evaluation of healthcare reforms, clinical process improvement and patient safety, as well as clinical practice change and patient-provider collaboration and service co-production.

Oslo universitetssykehus HF (OUS)

website

Oslo universitetssykehus HF is a highly specialised hospital in charge of national, regional and local hospital assignments. The hospital is Scandinavia’s largest and carries out more than 1.2 million patient treatments yearly. OUS’ main tasks are patient treatment and care, research, education and training of health personnel, and education and training of patients and their next-of-kin.

The Institute for Cancer Research (ICR, https://ous-research.no/institute/) has since its foundation in 1954 at OUS played a central role within the field of cancer research both in Norway and internationally. ICR has a track record of successful collaborative research projects between basic and clinical sciences, as well as industrial development facilitated by strong technological capabilities of infrastructure and service core facility developing new technologies and serving the user community. The emphasis on translational science and precision oncology has resulted in numerous clinical protocols based on in-house research, and ICR is a key partner in the Comprehensive Cancer Center (CCC), organized under OUS. The Department of Pathology at OUS has a longstanding tradition of international collaborative research in the field of (tumour) immunology.

Role in PANCAIM:

OUS will contribute both to the AI developments, as well as clinical data collection and curation,  experimental validation and clinical translation.

key staff

Tero Aittokallio

Show Bio
Tero Aittokallio, PhD has 20+ years of experience in network-centric and machine learning-based approaches for translational research (https://www.ousresearch.no/aittokallio/).

Caroline Verbeke

Show Bio
Caroline Verbeke, MD, PhD has a longstanding track record in pancreatic pathology and she is actively involved in diagnostic development as well as research at an international level (OUH – Pancreatic pathology research group (ous-research.no).

Elin H. Kure

Show Bio
Elin H Kure, PhD, MPH has 20+ years of experience in translational research in pancreatic and colorectal cancers.

Gry AA. Geitvik

Show Bio
Gry AA. Geitvik, BLS has 20+ years of experience in human biobanking and regulatory aspects.

Knut J. Labori

Show Bio
Knut J. Labori, MA, PhD is a Head of Pancreatic Surgery and Lead of the Pancreatic Cancer Research Group at OUS.

Spanish National Cancer Research Center (CNIO)

website

CNIO belongs to the Instituto de Salud Carlos III. It is a public foundation linked to the Ministry of Science and Innovation and the Ministry of Health. It employs, around, 400 persons (scientists, support, and administration). CNIO is one of the Severo Ochoa Centres of Excellence in Spain. CNIO hosts 26 research groups, as well as support Units, organized in 7 scientific programs (Molecular Oncology, Cancer Cell Biology, Structural Biology, Human Cancer Genetics, Clinical Research, Experimental Therapeutics and Biotechnology) in the areas of Basic and Translational Cancer Research. It is recognized as one of the leading cancer research institutions worldwide and it ranks very high in the various international evaluations of biomedical research institutions. CNIO also has a long track-record of achievements in the area of drug development and innovation, with the activities of the Experimental Therapeutics Program and the licensing of several of the molecules discovered at CNIO to major pharmaceuticals. CNIO has established partnerships with national and international hospitals, research centres, Universities, biotechnological and pharmaceutical companies. CNIO is deeply committed with society and it promotes multiple activities direct to the general public, secondary and high school students, and society in general. The Communication department is committed to develop a coherent and homogenous strategy to disseminate cancer information and the major research activities of the center, in particular. The scope of the research carried out by the Genetic and Molecular Epidemiology Group (GMEG) ranges from the identification of aetiological agents and mechanisms, to the translation of the findings into the clinical and Public Health domains, focusing on bladder, pancreatic, and breast cancers. GMEG employs a wide variety of biomarkers to better characterise exposures, genetic susceptibility patterns, and cancer outcomes. Omics data provide a unique opportunity in this regard and the Group explores its integration in epidemiologic studies. The strategic goals of the Group are to: 1) Identify non-genetic and genetic factors, as well as their interactions, associated with cancer development and progression and with its molecular/omics subphenotypes; 2) Develop and apply statistical-AI/bioinformatics tools to model the risk and course of patients with cancer by integrating epidemiologic and clinical data with omics information; and 3) Assess clinical and public health strategies for cancer control using current genomic tests and data.

 

Role in PANCAIM:

  • To coordinate and perform AI analysis to correlate radiomics, pathomics, transcriptomics, genomics, and clinical features,
  • contributor to define and annotate data relevant in the project. To upload data to the system,
  • contributor to provide a list of ranked omics features to be considered in the analyses, to conduct statistical models, and to interpret results.
key staff

Núria Malats

Show Bio
Núria Malats was born in 1962 in Barcelona, Spain. She obtained her MD in 1986 and her PhD in 1995 from the Universitat Autònoma de Barcelona and was one of the first scientists working in genetic and molecular epidemiology in Spain. From 1992-1995 she coordinated a national multicentre project on the molecular epidemiology of pancreatic cancer (PANKRAS2). In 1996 she was Visiting Scientist at the International Agency for Research on Cancer (IARC-WHO) in Lyon, France, where she trained until 1998 in genetic epidemiology. She then returned to Spain in 1998 and obtained a research contract from the Ministry of Health. Prior to joining the CNIO in 2007 she was a Scientist at the Centre de Recerca en Epidemiologia Ambiental (CREAL-IMIM, Barcelona), leading and participating in national and international competitively funded projects, and also coordinated the Spanish research network on bladder cancer. She is PI of the European Study on Pancreatic Cancer Genetics and Epidemiology (PanGen-EU) and co-PI of the Spanish Bladder Cancer/EPICURO Study, both being large case-control/cohort studies integrating scientific interests from different disciplines in cancer development and progression. Malats is the Spanish delegate of the Public Health Genomics European Network (PHGEN) and has participated in teaching programmes for underand post-graduate courses at several universities. She is Member of the Scientific Board of the European Society of Urological Research (ESUR) and the European Association of Urology Research Foundation.

Evangelina López de Maturana

Show Bio
Evangelina López de Maturana, PhD has a strong statistical background, broad experience working with genomic data, and extensive experience performing association studies for pancreatic and bladder cancer risk (GWAS) and prognosis, as well as studying predictive models for those traits. She is employed at CNIO as a member of the Genetic & Molecular Epidemiology Group.

Silvia Pineda

Show Bio
Silvia Pineda, PhD is trained in bioinformatics in USCF, USA, with experience on omics integrations and immunology. She is employed at CNIO as a member of the Genetic & Molecular Epidemiology Group.

Lola Alonso

Show Bio
Lola Alonso, BSc has broad experience in omics data analysis: genome, transcriptome, methylome, microbiome. She is employed at CNIO as a member of the Genetic & Molecular Epidemiology Group.

Vanesa Moreno

Show Bio
Vanesa Moreno, CE, MSc acting as the data manager of GMEG. She is employed at CNIO as a member of the Genetic & Molecular Epidemiology Group.

University of Glasgow (UOG)

website

Founded in 1451, the University of Glasgow is the fourth oldest university in the English-speaking world. It is one of the top 100 of the world’s universities.

Role in PANCAIM:

In this project, University of Glasgow / Glasgow Precision Oncology Laboratory (GPOL) will contribute 6 pancreatic cancer patient cohorts that are fully genomically and transcriptomically characterised to the PANCAIM project with its associated pathology and radiology data. The 5 prospectively recruited clinical trial cohorts (Precision-Panc PRIMUS-001 to -005) represents > £15M investments from Cancer Research UK, MRC, Celgene, Astra Zeneca, University of Glasgow and others. GPOL is a world leader in cancer genomics and personalised medicine, specifically pancreatic cancer, and will contribute both data and expertise in the area to PANCAIM. GPOL also contribute to PANCAIM with its significant experience in the discovery, development and translation of biomarkers of prognosis and therapeutic responsiveness in pancreatic cancer using genomics, clinical, pathology and the combination of.

key staff

David Chang

Show Bio
Dr David Chang, MBBS. MS. FRACS. FRCS (Glasg). PhD, is a Reader and Honorary Consultant Pancreatic Surgeon. His is a consultant pancreatic surgeon as part of the West of Scotland Pancreatic Unit, a tertiary referral unit for all pancreatic disease, that serves a population of 1.8 million. Provision of supervision and mentorship for junior medical staff in training and fourth year medical students from University of Glasgow.

Collective Minds Radiology (CM)

website

Collective Minds Radiology is a healthcare collaboration company. Our services include clinical consultation, sponsored and academic research, and education. We help institutions and consortiums to build healthcare data repositories and analysis tools. Headquartered in Stockholm Sweden with product engineering in Barcelona, Spain partnering with customers all over Europe.

Role in PANCAIM:

Most of the CM tasks are related to design, develop, run and maintain the data repository. CM will design and develop a repository that is flexible enough to handle the multiplemodality data, initially from the committed data assets and over time new prospective data. CM will create a legal framework to comfort data contributors, allows for participants to get access and protects patients’ privacy and run, update and maintain the data repository to ensure quick and reliable functionality and access to all data throughout the duration of the project. CM will take part in the long-term sustainability strategy of the repository.

key staff

Anders Nordell

Show Bio
Anders Nordell, MSs (Chief Executive Officer & Co-founder) is responsible for business development and sales. Anders has a 20- year career in MedTech with experience from Karolinska, Stanford and most recently as a commercial leader at GE Healthcare, responsible for imaging equipment sales teams in the Nordic region. https://www.linkedin.com/in/anders-nordell-849b1456/

Lennart Blomqvist

Show Bio
Professor of radiology, Lennart Blomqvist, MD (Chief Medical Officer & Co-founder) is our radiology expert with +30 years in oncologic radiology. Lennart is the director of R&D and innovation at Karolinska University Hospital in Stockholm. https://www.linkedin.com/in/lennart-blomqvist-05291419/

Pär Kragsterman

Show Bio
Pär Kragsterman, MSc, (CTO & Co-founder) is our CTO and leads the technical development. Pär has previously been the global IT-architect for PepsiCo. He has a 20-year career in building and managing global IT platforms. https://www.linkedin.com/in/pkragsterman/

Johan Norling

Show Bio
Johan Norling, MSc is leading the product department. He has worked in MedTech for the past 20 years and most recently as General Manager for GE Healthcare Nordic. Johan has a vast industry network and has a proven track record of delivering commercial results. https://www.linkedin.com/in/johan-norling-34b6b31/

Siemens Healthineers (SHS)

website

Siemens Healthineers is one of the largest technology providers for medical imaging technology, laboratory diagnostics, and clinical IT solutions, with about 50,000 employees in over 70 countries. Siemens Healthineers is a pioneer in the use of AI for medical applications for more than 20 years, with more than 700 patents and patent applications related to machine learning, of which more than 275 are rooted in deep learning. With over 60 AI-enriched offerings already on the market, established AI expertise, future-oriented staff, vast medical data sets, and the exceptional computing power needed for creating algorithm-supported healthcare solutions, Siemens Healthineers is the right partner for innovation and development of AI-powered applications.

Role in PANCAIM:

In this project, Siemens Healthineers will contribute to development of AI algorithms, system integration, and clinical validation of AI solutions in teamplay Digital Health Platform.

key staff

Tobias Heimann

Show Bio
Tobias Heimann is head of the research group “Artificial Intelligence Germany” at Siemens Healthineers.

Michael Kelm

Show Bio
Michael Kelm is the head of Pre-Development for the teamplay Digital Health Platform at Siemens Healthineers.

Arnaud Arindra Adiyoso Setio

Show Bio
Arnaud Arindra Adiyoso Setio is a research scientist at Siemens Healthineers focusing on computer-aided diagnosis, medical image processing, and deep learning.

Manasi Datar

Show Bio
Manasi Datar is a research scientist at Siemens Healthineers with experience in medical image analytics, computational anatomy, and deep learning.

Monica Toma

Show Bio
Monica Toma is a research and collaboration manager at Siemens Healthineers.

The Hyve (HYVE)

website

The Hyve is an innovative international company, focused on providing software development, data management tools and services for clinical and biomedical data. We do this by building on existing open source software and communities. Our mission is to empower scientists with user-friendly software to organize, visualize, publish and share their research data. The core values of The Hyve are sharing, reuse and specialization. We provide several services to our customers, ranging from customization of tools to data hosting in the cloud. Most of our customer activities are either in translational medicine, where we work with pharmaceutical companies or academic hospitals and research organizations. The Hyve has joined several precompetitive initiatives and is active in the field of FAIR (Findable, Accessible, Interoperable and Reusable) data management.

Role in PANCAIM:

Within the PANCAIM project, the main task of The Hyve will be to provide a FAIR research platform. This platform will allow the researchers within the consortium to add their data with rich metadata, resulting in a overview of all available data. To do this, The Hyve will use its expertise in FAIR data management to extend the Fairspace tool.

key staff

Julia Kurps

Show Bio
Julia Kurps PhD will contribute as primary contact point and project manager from The Hyve.

Maria Escala Garcia

Show Bio
Maria Escala Garcia PhD will contribute in her role as Business Analyst and will focus on the data management plan creation and requirements gathering.

Elena Garcia Lara

Show Bio
Elena Garcia is Lara Data Engineer with experience in ML/AI and OMOP common data model for clinical data.

Frank van den Berg

Show Bio
Frank van den Berg is Software Engineer with extensive experience in backend software development and databases, will focus on repository requirements gathering and developments on Fairspace .

AMIRES (AMI)

website

AMIRES is a consulting and management company for research, development and innovation projects, which provides the necessary strategic and administrative support to high quality international teams to achieve their objectives and facilitates the research-industrial and research-policy making interface. AMIRES follows projects from their initiation and planning, through negotiation, execution and management to the final stage, where exploitation of new technologies, products or services is facilitated. Moreover, main mission of the company is to facilitate the access of European research to high-tech SMEs and improve exploitation of innovative ideas. AMIRES s. r. o. is based in the Czech Republic but provides its services all around Europe.

Role in PANCAIM:

Within the project, AMIRES is be actively involved in the administrative and financial project management tasks and is responsible for the dissemination activities.

key staff

Kristina Nehilčová – Project manager

Show Bio
Kristina Nehilčová is PANCAIM Project Manager. Within AMIRES, Kristina is responsible for projects in the health and biotechnology domains.

Rudolf Fryček

Show Bio
Rudolf Fryček Ph.D. is the CEO of AMIRES and he has more than 15 years’ experience in the European project management and consultancy.

Lenka Bajarová

Show Bio
Lenka Bajarová is a Managing Director of AMIRES s. r. o. Lenka runs the Czech branch of AMIRES and is responsible for management and dissemination of several H2020 funded projects.